Scaled API and increasingly sophisticated biologics. Compare Chinese CDMOs across API synthesis, biologics, and small molecules — by capability, certification, and site.
China is one of the two dominant API-manufacturing nations and has invested heavily in moving up the value chain into biologics, cell therapy, and integrated discovery-through-manufacture services. Its largest players operate at a scale and speed that few markets can match, with rapidly improving quality infrastructure.
Manufacturing is concentrated around the Yangtze River Delta (Shanghai, Suzhou, Wuxi), the Pearl River Delta, and Beijing–Tianjin. These hubs combine large-scale chemistry, growing biologics capacity, and dense supplier ecosystems for intermediates and raw materials.
The BIOSECURE Act has made China the central variable in global outsourcing strategy. While pharmaceutical products are not banned, sponsors — especially those touching US government funding — are actively de-risking by qualifying second sources in India, Europe, and the US. China remains a major global player, but supply-chain dual-sourcing is now the prevailing strategy.
No companies found in this category yet. Check back soon.
Browse all CDMOsHow this list is built: companies appear here when they have a manufacturing site in China in our facilities dataset and pass the marketplace eligibility gate (pharmaceutical contract manufacturers only — CROs, equipment suppliers, and other non-manufacturers are excluded). Read the full methodology for the eligibility gates and how our ranked lists are computed.
Our AI Matchmaker analyzes your project requirements and matches you with qualified China manufacturing partners. Free for buyers.